StemCell Therapy

BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas BioPharma, will present at the ThinkEquity Investment Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental Hotel in New York City.

See the article here:
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21.

Visit link:
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203

Read the rest here:
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding...

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced the company will present at the 2022 American Academy of Optometry’s Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center. Presentation details are below:

Here is the original post:
Eyenovia to Present at the American Academy of Optometry’s Annual Meeting

WESTLAKE VILLAGE, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The results were presented as a poster at the 2022 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The online survey was conducted by The Harris Poll on behalf of Arcutis and included 300 U.S. adults (18+ years of age) who had been diagnosed with seborrheic dermatitis by a healthcare provider, of which 84% reported their current condition to be moderate or severe, and 601 licensed U.S. healthcare providers specializing in dermatology, including dermatologists, nurse practitioners (NPs), and physician assistants (PAs).

Continued here:
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

Continue reading here:
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension

See the original post here:
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd...

Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence

See more here:
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall...

HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has entered into an agreement regarding the sale of certain of its legacy assets comprised of its inner ear therapeutics research and development programs and a license to use its RNA delivery technology in certain inner ear applications to a European family office (the “Buyer”), in a multi-step process.

Excerpt from:
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).

Read more from the original source:
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

21.10.2022 at 18:30

More here:
Orion Corporation: Acquisition of Own Shares 21.10.2022

MANCHESTER, United Kingdom, Oct. 21, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need, today announced at IDWeek 2022 positive data from the first 100 patients who completed study treatment in its ongoing Phase 2b open-label study (Study 32, NCT03583164) of oral olorofim as a treatment for invasive fungal infections.

Read the original post:
F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with...

Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that a scientific abstract has been selected for poster presentation at the upcoming The Liver Meeting® 2022 hosted by the American Association for the Study of Liver Diseases on November 4-8, 2022 in Washington, DC.

Read more:
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL.

Visit link:
Burning Rock Announces Publication of Registration Document and Potential Direct Listing on the London Stock Exchange

MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET.

View post:
Syneos Health Schedules Third Quarter 2022 Earnings Call for Friday, November 4, 2022

LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-K, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").

Go here to see the original:
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K

- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation -

The rest is here:
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking...

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

Read this article:
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell...

AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease, Pancreatic Cancer, and DIPG, today announced that the Company will be presenting at the upcoming SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, MA.

Visit link:
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting

SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovarian cancer. The findings reveal disconnects between perceived health knowledge and proactive actions taken in response.

See original here:
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds